Predictive histopathological markers for upstaging to invasive carcinoma after a biopsy diagnosis of ductal carcinoma in situ (DCIS) of the breast: a hypothesis-generating systematic review.

IF 2 4区 医学 Q3 CELL BIOLOGY
Pathobiology Pub Date : 2025-07-26 DOI:10.1159/000547335
Julia A M Riggi, Ibrahim Kassem, Christine Galant, Carolien H M Van Deurzen, Martine Berlière, Mieke R Van Bockstal
{"title":"Predictive histopathological markers for upstaging to invasive carcinoma after a biopsy diagnosis of ductal carcinoma in situ (DCIS) of the breast: a hypothesis-generating systematic review.","authors":"Julia A M Riggi, Ibrahim Kassem, Christine Galant, Carolien H M Van Deurzen, Martine Berlière, Mieke R Van Bockstal","doi":"10.1159/000547335","DOIUrl":null,"url":null,"abstract":"<p><p>Introduction Around 25% of patients with a biopsy diagnosis of pure ductal carcinoma in situ (DCIS) will be upstaged to invasive breast carcinoma (IBC) after surgery. Because of this upstaging risk, patients with high grade DCIS frequently undergo a sentinel lymph node procedure (SLNP), which can cause surgery-induced morbidity. Presentation with a palpable mass increases the upstaging risk, but histopathological predictors are currently unclear. This PROSPERO-registered systematic review aims to identify which biopsy-based histopathological markers can predict the presence of IBC in the subsequent resection. These results might help to reserve SLNPs for selected high-risk patients, aiming to personalize treatment. Methods PubMed, Embase and Scopus were searched for content using predefined search queries. Three reviewers independently screened the literature in Rayyan by applying predefined criteria. Studies including DCIS with micro-invasion were excluded. Results This review comprised 36 studies, of which 33 were retrospective, representing 18475 patients. The median cohort size was 267 patients (range: 67-3780). The median upstaging risk was 26% (range: 8-52%). The reports studied twenty-three histopathological and immunohistochemical features. Only seven features were investigated in multiple studies, all yielding contradictory results. For instance, thirty-three studies investigated nuclear grade, but only 18 reports demonstrated a significant association with upstaging, independent from cohort size. Conclusion No robust histopathological features can be recommended at present to reliably predict the upstaging risk to IBC after biopsy-diagnosed pure DCIS. We discuss several hypotheses, aiming to explain these contradictory data. Ideally, large-scale multicentre prospective studies should be organised to answer this unmet clinical need.</p>","PeriodicalId":19805,"journal":{"name":"Pathobiology","volume":" ","pages":"1-22"},"PeriodicalIF":2.0000,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathobiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547335","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction Around 25% of patients with a biopsy diagnosis of pure ductal carcinoma in situ (DCIS) will be upstaged to invasive breast carcinoma (IBC) after surgery. Because of this upstaging risk, patients with high grade DCIS frequently undergo a sentinel lymph node procedure (SLNP), which can cause surgery-induced morbidity. Presentation with a palpable mass increases the upstaging risk, but histopathological predictors are currently unclear. This PROSPERO-registered systematic review aims to identify which biopsy-based histopathological markers can predict the presence of IBC in the subsequent resection. These results might help to reserve SLNPs for selected high-risk patients, aiming to personalize treatment. Methods PubMed, Embase and Scopus were searched for content using predefined search queries. Three reviewers independently screened the literature in Rayyan by applying predefined criteria. Studies including DCIS with micro-invasion were excluded. Results This review comprised 36 studies, of which 33 were retrospective, representing 18475 patients. The median cohort size was 267 patients (range: 67-3780). The median upstaging risk was 26% (range: 8-52%). The reports studied twenty-three histopathological and immunohistochemical features. Only seven features were investigated in multiple studies, all yielding contradictory results. For instance, thirty-three studies investigated nuclear grade, but only 18 reports demonstrated a significant association with upstaging, independent from cohort size. Conclusion No robust histopathological features can be recommended at present to reliably predict the upstaging risk to IBC after biopsy-diagnosed pure DCIS. We discuss several hypotheses, aiming to explain these contradictory data. Ideally, large-scale multicentre prospective studies should be organised to answer this unmet clinical need.

乳腺导管原位癌(DCIS)活检诊断后浸润性癌的预测组织病理学标志物:一项假设生成的系统综述。
大约25%的活检诊断为单纯导管原位癌(DCIS)的患者在手术后会被诊断为浸润性乳腺癌(IBC)。由于这种风险,高级别DCIS患者经常接受前哨淋巴结手术(SLNP),这可能导致手术引起的发病率。可触及肿块的表现增加了占上风的风险,但组织病理学预测目前尚不清楚。这项普洛斯彼罗注册的系统评价旨在确定哪些基于活检的组织病理学标志物可以预测随后切除术中IBC的存在。这些结果可能有助于为选定的高危患者保留SLNPs,以实现个性化治疗。方法采用预定义的检索词对PubMed、Embase和Scopus进行检索。三位审稿人通过应用预先确定的标准独立筛选Rayyan的文献。排除DCIS伴微侵的研究。结果本综述共纳入36项研究,其中33项为回顾性研究,共纳入18475例患者。中位队列大小为267例患者(范围:67-3780)。中位占优风险为26%(范围:8-52%)。报告研究了23个组织病理学和免疫组织化学特征。只有7个特征在多个研究中被调查,所有这些研究都得出了相互矛盾的结果。例如,33项研究调查了核分级,但只有18项报告显示与占优有显著关联,独立于队列大小。结论目前没有可靠的组织病理学特征可以可靠地预测活检诊断的纯DCIS后IBC的前期风险。我们讨论了几个假设,旨在解释这些相互矛盾的数据。理想情况下,应该组织大规模的多中心前瞻性研究来回答这一未满足的临床需求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pathobiology
Pathobiology 医学-病理学
CiteScore
8.50
自引率
0.00%
发文量
47
审稿时长
>12 weeks
期刊介绍: ''Pathobiology'' offers a valuable platform for the publication of high-quality original research into the mechanisms underlying human disease. Aiming to serve as a bridge between basic biomedical research and clinical medicine, the journal welcomes articles from scientific areas such as pathology, oncology, anatomy, virology, internal medicine, surgery, cell and molecular biology, and immunology. Published bimonthly, ''Pathobiology'' features original research papers and reviews on translational research. The journal offers the possibility to publish proceedings of meetings dedicated to one particular topic.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信